Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130022/S069

HFX Dynamis System

Nevro Corporation · Decision date Aug 18, 2026

FDA DECISIONP130022/S069

What did the FDA approve?

FDA records P130022/S069 as a supplement to PMA P130022, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 18, 2026.

FDA approval order statement

This supplement (S069) requested approval for the next generation implantable pulse generator system referred to as the HFX Dynamis System. The HFX Dynamis System is designed to deliver a new stimulation therapy, Bolus 10kHz, and support expanded MRI access to allow for scanning with one broken conductor per percutaneous lead. The key changes approved in this supplement include: a new Implantable Pulse Generator model (IPG3500), an updated Patient Application (PTA10043, v3.0.0), and updated Clinician Programmer Software (v4.0). The device, as modified, will be marketed under the trade name HFX Dynamis System and is indicated as follows:The HFX Dynamis System, HFX iQ System and HFX Trial System are indicated as aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain, and leg pain. The HFX Dynamis System, HFX iQ System and HFX Trial System, when programmed to include a frequency of 10 kHz, are indicated as aids in the management of chronic intractable pain of the lower limbs, including unilateral or bilateral pain, associated with diabetic neuropathy. The HFX Dynamis System, HFX iQ System and HFX Trial System, when programmed to include a frequency of 10 kHz, are indicated as aids in the management of non-surgical refractory back pain (intractable back pain without prior surgery and not a candidate for back surgery). FDA's review of this PMA supplement also included the review and approval of a PCCP: Juno Predetermined Change Control Plan, Rev A., which includes two future firmware modifications: 1. Disabling the 1 MHz ASIC clock while in MRI Mode for the IPG3000 and IPG3500, to reduce RF artifacts in MRI images; and 2. Optimizing power consumption for bolus therapy programs by disabling the ASIC during the bolus Macro Off Time, applicable to the IPG3500 only.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Neurology
Decision date
Aug 18, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P130022/S069
Regulatory pathway
PMA supplement
Product code
LGW
Decision code
APPR
Decision date
Aug 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.

Product code
LGW
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P130022/S069 received

    Application receipt date recorded by FDA.

  2. P130022/S069 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P130022. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130022

Product / regulatory recordCompanyPathwayDecision dateSource
Nevro CorporationPMA supplementAug 15, 2025FDA

Explore the linked device profile

Other records with product code LGW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Nevro Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1800 Bridge Pkwy., Redwood City, CA, 94065

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records